| abstract |
A method of treating Triple Negative Breast Cancer in a subject, which comprises delivering a nucleic acid sequence encoding a mutant Erb B-2 polypeptide in an amount effective to inhibit cancer cell proliferation, wherein the mutant Erb B-2 lacks a functional nuclear localization signal, cannot translocate to the nucleus of the cell in which it is present, and functions as a dominant-negative inhibitor of endogenous Erb B-2 by inhibiting nuclear translocation of endogenous Erb B-2 in the cell in which the mutant is present, wherein the mutant Erb B-2 polypeptide retains intrinsic tyrosine kinase activity and does not inhibit endogenous Erb B-2 tyrosine kinase activity. |